All In Biotech

Drug Trial Radar · NCT01920711

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction (PARAGON-HF)

Last checked: Nov 19, 2026Latest source record: Sep 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,822 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,822

Actual

Start

Jul 18, 2014

Primary completion

Jun 7, 2019

Study completion Jun 7, 2019

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 12, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.

Conditions

  • Heart Failure With Preserved Ejection Fraction

Interventions

  • LCZ696Drug

    LCZ696 50mg, 100mg and 200 mg dosage strengths will be available for dose adjustments.

  • ValsartanDrug

    Valsartan 40mg, 80mg and 160mg dosage strengths will be available for dose adjustments.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations.Time frame: Total follow up time (up to 57 months)

Locations

715 sites in 43 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Huntsville, Alabama

  • Novartis Investigative Site

    Mobile, Alabama

  • Novartis Investigative Site

    Muscle Shoals, Alabama

  • Novartis Investigative Site

    Little Rock, Arkansas

  • Novartis Investigative Site

    Beverly Hills, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Northridge, California

  • Novartis Investigative Site

    Orange, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    Santa Ana, California

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Hartford, Connecticut

  • Novartis Investigative Site

    New Haven, Connecticut

  • Novartis Investigative Site

    Stamford, Connecticut

  • Novartis Investigative Site

    West Haven, Connecticut

  • Novartis Investigative Site

    Bradenton, Florida

  • Novartis Investigative Site

    Gainesville, Florida

  • Novartis Investigative Site

    Lake Worth, Florida

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Tallahassee, Florida

  • Novartis Investigative Site

    Atlanta, Georgia

  • Novartis Investigative Site

    Atlanta, Georgia

  • Novartis Investigative Site

    Covington, Georgia

  • Novartis Investigative Site

    Cumming, Georgia

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Evanston, Illinois

  • Novartis Investigative Site

    Hazel Crest, Illinois

  • Novartis Investigative Site

    Lombard, Illinois

  • Novartis Investigative Site

    Maywood, Illinois

  • Novartis Investigative Site

    Oakbrook Terrace, Illinois

  • Novartis Investigative Site

    Peoria, Illinois

  • Novartis Investigative Site

    Quincy, Illinois

  • Novartis Investigative Site

    Louisville, Kentucky

  • Novartis Investigative Site

    Baton Rouge, Louisiana

  • Novartis Investigative Site

    Hammond, Louisiana

  • Novartis Investigative Site

    Lafayette, Louisiana

  • Novartis Investigative Site

    Slidell, Louisiana

  • Novartis Investigative Site

    Biddeford, Maine

  • Novartis Investigative Site

    Portland, Maine

Showing 40 of 715 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.